<DOC>
	<DOCNO>NCT00414622</DOCNO>
	<brief_summary>A Double Blind , Placebo-Controlled Randomized Study Compare Safety Tolerability GTS-21 ( 25 Mg TID , 50 Mg TID , 75 Mg TID 150 Mg TID ) When Administered Daily 28 Days Participants With Probable Alzheimer ’ Disease</brief_summary>
	<brief_title>GTS21-201 Alzheimer Disease : GTS-21 Administered Daily 28 Days Participants With Probable Alzheimer ’ Disease</brief_title>
	<detailed_description>A Double Blind , Placebo-Controlled Randomized Study Compare Safety Tolerability GTS-21 ( 25 Mg TID , 50 Mg TID , 75 Mg TID 150 Mg TID ) When Administered Daily 28 Days Participants With Probable Alzheimer ’ Disease</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>3- ( 2,4-dimethoxybenzylidene ) anabaseine</mesh_term>
	<criteria>probable Alzheimer others</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Probable Alzheimer disease</keyword>
</DOC>